pralsetinib
Selected indexed studies
- Pralsetinib. (, 2012) [PMID:37665754]
- Pralsetinib: First Approval. (Drugs, 2020) [PMID:33136236]
- Pralsetinib. (, 2006) [PMID:33226746]
_Worker-drafted node — pending editorial review._
Connections
pralsetinib is a side effect of
Sources
- Pralsetinib. (2012) pubmed
- Pralsetinib: First Approval. (2020) pubmed
- Pralsetinib. (2006) pubmed
- Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC. (2022) pubmed
- Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer. (2022) pubmed
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. (2021) pubmed
- PMID:40504957 (2022) pubmed
- Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. (2022) pubmed
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. (2021) pubmed
- PMID:38498627 (2023) pubmed